Abstract:1459 Introduction: Actinium-225 (t1/2=10.0 d, 100% α) is considered as the next generation nuclide for Targeted radionuclide therapy (TRT). Ac-225 emits 4 α-particles and 2 β-particles in a row, which is considered as one of the most potent radionuclides against cancer. In general, ED50 of Ac-225 is 3-order lower than that of Lu-177. However, the limited supply of Ac-225 has hampered its research and further clinical application. In general, Actinium-225 is generated from Uranium-233 decay and the production of Ac-225 is <2 Ci per year. The other possible strategy to produce Ac-225 is from accelerator through 232Th(p, x)225Ac reaction on high-energy accelerator. In this study, we used 100 MeV protons to irradiate natural ThO2 target with CYCIAE-100 (100 MeV H-, 500 μA) and produced Ac-225. To isolate Ac-225 from other side products, we optimized the purification process, which consists of cation-exchange and solid-phase extraction with AG50W-X8 resin, DGA resin, and TRU resin to avoid liquid-liquid extraction. At last, high radiochemical purity Ac-225 product was obtained with ideal recovery rate. Methods: ThO2 powder was prepared as the target materials from analytically pure Th(NO3)4. The ThO2 powder was put into a niobium-made powder target and irradiated with about 2 μA 100 MeV proton (CYCIAE-100) and cooled with rapid airflow. 10 days cooling after end of beam (EOB), the irradiated ThO2 powder was dissolved in hot HNO3- HF and reconstituted in citric acid. AG50W-X8 cation exchanger resin, DGA resin and TRU resin were applied to the isolation process with solid-phase extraction. The qualitative and quantitative analysis of nuclear was done with HPGe Gamma-ray spectroscopy detector. Results: 619 µCi (EOB) of Ac-225 were produced with 7.18±1.08 mb experiment cross-sections. The abundance of Ac-225 of the irradiated ThO2 powder is still less than 3%, leading to the challenge for Ac-225 isolation. The optimized the purification process, which consists of cation-exchange and solid-phase extraction with AG50W-X8 resin, DGA resin, and TRU resin without liquid-liquid extraction, made the successful isolation for over 200 µCi of Ac-225 with radiochemical purity > 99.5%, recovery rate ~95% and < 4 hours time-cost. Conclusions: By using a 100 MeV cyclotron, we have successfully performed a pilot study of production and isolation of Ac-225, demonstrating the possibility of producing Ac-225 with the cyclotron in China.

Dielectric and piezoelectric properties of modified (Na, K)NbO3 ceramics substituted with KNbO3

Actinium-225 Production with an Electron Accelerator

Semi-Permanent Mass Production of Ac-225 for Cancer Therapy by the (3n,x) Reaction in Pressurized Water Reactor

225Ac production via 226Ra (μ−, n ν) 225Fr reaction with 226Ra target

Medical students’ clinical performance in general practice – Triangulating assessments from patients, teachers and students

Production and Isolation of Actinium-225 for Targeted Radiotherapy with a 100 MeV Proton Cyclotron and Solid-Phase Extraction

Production and purification of molecular 225Ac at CERN-ISOLDE

The Cyclotron Production of Actinium-225 in CYCIAE-100

Production of 225 Ac for medical application from 232 Th-metallic targets in Nb-shells irradiated with middle-energy protons

Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy

Actinium-225 Targeted Agents: Where Are We Now?

Potential production of Ac-225 at Egyptian second research reactor (ETRR-2) through neutron induced transmutation of Ra-226

In vivo quantitative SPECT imaging of actinium-226: feasibility and proof-of-concept

Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications

Effect of 226Ra purity as a target for 225Ac production using a fast reactor

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy

Tales of a Hobbesian Cynic

Conformal curves on the WO3 surface.

Production, purification and formulation of nanoradiopharmaceutical with 211At: An emerging candidate for targeted alpha therapy

Development of 225Ac-doped biocompatible nanoparticles for targeted alpha therapy

Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa